Simultaneously optimized support vector regression combined with genetic algorithm for qsar analysis of kdr/vegfr-2 inhibitors

Chemical Biology and Drug Design

Volumn 75, Issue 5, 2010, Pages 494-505

  Sun, Min ^a   Chen, Junqing ^a   Cai, Jin ^a   Cao, Meng ^a   Yin, Shuangqing ^a   Ji, Min ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

Genetic algorithm; KDR VEGFR 2 inhibitors; Quantitative structure activity relationship; Support vector regression

Indexed keywords

INDAZOLE DERIVATIVE; NAPHTHALENE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 INHIBITOR;

ANALYTIC METHOD; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG STRUCTURE; EVALUATION; EXTERNAL VALIDITY; GENETIC ALGORITHM; INTERMETHOD COMPARISON; MATHEMATICAL COMPUTING; MULTIPLE LINEAR REGRESSION ANALYSIS; PARAMETRIC TEST; PERFORMANCE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STATISTICAL MODEL; STRUCTURE ANALYSIS; SUPPORT VECTOR MACHINE; VALIDATION PROCESS;

ALGORITHMS; INDAZOLES; LINEAR MODELS; NAPHTHALENES; PROTEIN STRUCTURE, TERTIARY; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77949997095     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2010.00958.x     Document Type: Article

References (42)

1. Risau W. (1997) Mechanisms of angiogenesis. Nature 386 : 671 674.
2. Ribatti D., Vacca A., Nico B., Roncali L., Dammacco F. (2001) Postnatal vasculogenesis. Mech Dev 100 : 157 163.
3. Gilbert M., Mousa S., Mousa S.A. (2008) Current status of anti-vascular endothelial growth factor (VEGF) strategies and future directions. Drugs Future 6 : 515 525.
4. Shawver L.K., Lipson K.E., Fong T.A.T., McMahon G., Plowman G.D., Strawn L.M. (1997) Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discov Today 2 : 50 63.
5. Ferrara N. (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2 : 795 803.
6. Carmeliet P., Jain R.K. (2000) Angiogenesis in cancer and other diseases. Nature 407 : 249 257.
7. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 : 391 400.
8. Schenone S., Bondavalli F., Botta M. (2007) Antiangiogenic agents: an update on small molecule VEGFR inhibitors. Curr Med Chem 14 : 2495 2516.
9. Baka S., Clamp A.R., Jayson G.C. (2006) A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets 10 : 867 876.
10. Faivre S., Demetri G., Sargent W., Raymond E. (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6 : 734 745.
11. Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R.A., Schwartz B., Simantov R., Kelley S. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5 : 835 844.
12. Harmange J.C., Weiss M.M., Germain J., Polverino A.J., Borg G., Bready J., Chen D. et al. (2008) Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluations. J Med Chem 51 : 1649 1667.
13. Bauer D., Whittington D.A., Coxon A., Bready J., Harriman S.P., Patel V.F., Polverino A., Harmange J.C. (2008) Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors. Bioorg Med Chem Lett 18 : 4844 4848.
14. Hill D.L. (1972) The Biochemistry and Physiology of Tetrahymena. New York, USA : Academic Press pp. 230
15. Sun M., Zheng Y.G., Wei H.T., Chen J.Q., Cai J., Ji M. (2009) Enhanced replacement method-based quantitative structure-activity relationship modeling and support vector machine classification of 4-anilino-3- quinolinecarbonitriles as Src kinase inhibitors. QSAR Comb Sci 28 : 312 324.
16. Mercader A.G., Duchowicz P.R., Fernández F.M., Castro E.A., Bennardi D.O., Autino J.C., Romanelli G.P. (2008) QSAR prediction of inhibition of aldose reductase for flavonoids. Bioorg Med Chem 16 : 7470 7476.
17. Toropov A.A., Toropova A.P., Benfenati E. (2009) QSAR modelling for mutagenic potency of heteroaromatic amines by optimal SMILES-based descriptors. Chem Biol Drug Des 73 : 301 312.
18. Mercader A.G., Duchowicz P.R., Fernandez F.M., Castro E.A., Wolcan E. (2008) QSPR study of solvent quenching of the D-5(0) -> F-7(2) emission of Eu(6,6,7,7,8,8,8-heptafluoro-2,2-dimethyl-3,5-octanedionate)(3). Chem Phys Lett 462 : 352 357.
19. Hemmateenejad B., Yazdani M. (2009) QSPR models for half-wave reduction potential of steroids: a comparative study between feature selection and feature extraction from subsets of or entire set of descriptors. Anal Chim Acta 634 : 27 35.
20. Hemmateenejad B., Elyasi M. (2009) A segmented principal component analysis-regression approach to quantitative structure-activity relationship modeling. Anal Chim Acta 646 : 30 38.
21. Toropov A.A., Rasulev B.F., Leszczynski J. (2008) QSAR modeling of acute toxicity by balance of correlations. Bioorg Med Chem 16 : 5999 6008.
22. Li H.D., Liang Y.Z., Xu Q.S. (2009) Support vector machines and its applications in chemistry. Chemom Intell Lab Syst 95 : 188 198.
23. Riahi S., Pourbasheer E., Ganjali M.R., Norouzi P. (2009) Support vector machine-based quantitative structure-activity relationship study of cholesteryl ester transfer protein inhibitors. Chem Biol Drug Des 73 : 558 571.
24. Riahi S., Pourbasheer E., Dinarvand R., Ganjali M.R., Norouzi P. (2008) Exploring QSARs for antiviral activity of 4-alkylamino-6-(2-hydroxyethyl)-2- methylthiopyrimidines by support vector machine. Chem Biol Drug Des 72 : 205 216.
25. Pourbasheer E., Riahi S., Ganjali M.R., Norouzi P. (2009) Application of genetic algorithm-support vector machine (GA-SVM) for prediction of BK channels activity. Eur J Med Chem 44 : 5023 5028.
26. Stewart J.J.P. (1989) Optimization of parameters for semiempirical methods I. Method. J Comput Chem 10 : 209 220.
27. Holland J.H. (1975) Adaption in Natural and Artificial Systems. Ann Arbor, USA : University of Michigan Press.
28. Lei B.L., Li J.Z., Liu H.X., Yao X.J. (2008) Accurate prediction of aquatic toxicity of aromatic compounds based on Genetic Algorithm and Least Squares Support Vector Machines. QSAR Comb Sci 27 : 850 865.
29. Cortes C., Vapnik V. (1995) Support-vector networks. Mach Learn 20 : 273 297.
30. Efron B. (1983) Estimating the error rate of a prediction rule: improvement on cross-validation. J Am Stat Assoc 78 : 316 331.
31. Osten D.W. (1988) Selection of optimal regression models via cross-validation. J Chemometr 2 : 39 48.
32. Tropsha A., Gramatica P., Gombar V.K. (2003) The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb Sci 22 : 69 77.
33. 2!. J Mol Graph Model 20 : 269 276.
34. Wold S., Eriksson L. (1995) Statistical validation of QSAR results. Validation tools. In : van de Waterbeemd H., editor. Chemometrics Methods in Molecular Design. Weinheim, Germany : Wiley-VCH p. 309 318.
35. Tute M. (1990) History and objectives of quantitative drug design in advances in drug research. In : Sammes P., Taylor J., editors. Comprehensive Medicinal Chemistry, Vol 4. Oxford : Pergamon p. 1 32.
36. Hansch C., Taylor J., Sammes P. (1990) Comprehensive Medicinal Chemistry: The Rational Design, Mechanistic Study & Therapeutic Application of Chemical Compounds, Vol. 6. New York : Pergamon p. 1 19.
37. Topliss J.G., Costello R.J. (1972) Chance correlations in structure-activity studies using multiple regression analysis. J Med Chem 15 : 1066 1078.
38. Topliss J.G., Edwards R.P. (1979) Chance factors in studies of quantitative strcuture-activity relationships. J Med Chem 22 : 1238 1244.
39. Todeschini R., Consonni V. (2000) Handbook of Molecular Descriptors. Weinheim, Germany : Wiley-VCH.
40. Sun M., Chen J.Q., Wei H.T., Yin S.Q., Yang Y., Ji M. (2009) Quantitative structure-activity relationship and classification analysis of diaryl ureas against vascular endothelial growth factor receptor-2 kinase using linear and non-linear models. Chem Biol Drug Des 73 : 644 654.
41. Sun M., Zheng Y.G., Wei H.T., Chen J.Q., Ji M. (2009) QSAR studies on 4-anilino-3-quinolinecarbonitriles as Src kinase inhibitors using robust PCA and both linear and nonlinear models. J Enzyme Inhib Med Chem 24 : 1109 1116.
42. Saiz-Urra L., Gonzalez M.P., Teijeira M. (2007) 2D-autocorrelation descriptors for predicting cytotoxicity of naphthoquinone ester derivatives against oral human epidermoid carcinoma. Bioorg Med Chem 15 : 3565 3571.